Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients

Takashi Kadowaki, Masakazu Haneda, Hiroshi Itoh, Kazuyo Sasaki, Sonoe Hiraide, Miyuki Matsukawa, Makoto Ueno

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Healthy eating is a critical aspect of the prevention and management of type 2 diabetes (T2DM). Disrupted eating patterns can result in poor glucose control and increase the likelihood of diabetic complications. Teneligliptin inhibits dipeptidyl peptidase-4 activity for 24 h and suppresses postprandial hyperglycemia after all three daily meals. This interim analysis of data from the large-scale post-marketing surveillance of teneligliptin (RUBY) in Japan examined eating patterns and their relationship with metabolic parameters and diabetic complications. We also examined whether eating patterns affected safety and efficacy of teneligliptin. Methods: We analyzed baseline data from survey forms collected in RUBY between May 2013 and June 2017, including patient characteristics, metabolic parameters, and eating patterns (eating three meals per day or not; timing of evening meal) before teneligliptin treatment was initiated. Safety and efficacy of 12 months’ teneligliptin (20–40 mg/day) treatment was assessed. Results: Data from 10,532 patients were available for analysis. Most patients who did not eat three meals per day (n =757) or who ate their evening meal after 10 PM (n =206) were 64 years old or younger. At baseline, glycated hemoglobin (HbA1c), fasting blood glucose, triglycerides, total and low-density lipoprotein cholesterol, body mass index, alanine aminotransferase, and aspartate aminotransferase levels were higher in those patients who did not eat three meals per day (p < 0.05) or who ate their evening meal late (p < 0.05). Diabetic complications were more common in patients who did not eat three meals per day. Treatment with teneligliptin reduced HbA1c over 6 or 12 months across all eating patterns, with a low incidence of adverse drug reactions. Conclusions: Eating patterns may be associated with altered metabolic parameters and diabetic complications among Japanese patients with T2DM. Teneligliptin may be well tolerated and improve hyperglycemia in patients with T2DM irrespective of eating patterns. Funding: Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co. Ltd. Trial Registration Number: Japic CTI-153047.

Original languageEnglish
Pages (from-to)817-831
Number of pages15
JournalAdvances in Therapy
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Marketing
Type 2 Diabetes Mellitus
Meals
Eating
Diabetes Complications
Therapeutics
Hyperglycemia
Dipeptidyl Peptidase 4
Safety
3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
Glycosylated Hemoglobin A
Aspartate Aminotransferases
Drug-Related Side Effects and Adverse Reactions
Alanine Transaminase
LDL Cholesterol
Blood Glucose
Fasting
Japan
Triglycerides
Body Mass Index

Keywords

  • Dipeptidyl peptidase-4 inhibitor
  • Eating pattern
  • HbA1c
  • Post-marketing surveillance
  • Teneligliptin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment : Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients. / Kadowaki, Takashi; Haneda, Masakazu; Itoh, Hiroshi; Sasaki, Kazuyo; Hiraide, Sonoe; Matsukawa, Miyuki; Ueno, Makoto.

In: Advances in Therapy, Vol. 35, No. 6, 01.06.2018, p. 817-831.

Research output: Contribution to journalArticle

Kadowaki, Takashi ; Haneda, Masakazu ; Itoh, Hiroshi ; Sasaki, Kazuyo ; Hiraide, Sonoe ; Matsukawa, Miyuki ; Ueno, Makoto. / Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment : Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients. In: Advances in Therapy. 2018 ; Vol. 35, No. 6. pp. 817-831.
@article{0816d915e0d3468ba83cdfa055bb1e00,
title = "Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients",
abstract = "Introduction: Healthy eating is a critical aspect of the prevention and management of type 2 diabetes (T2DM). Disrupted eating patterns can result in poor glucose control and increase the likelihood of diabetic complications. Teneligliptin inhibits dipeptidyl peptidase-4 activity for 24 h and suppresses postprandial hyperglycemia after all three daily meals. This interim analysis of data from the large-scale post-marketing surveillance of teneligliptin (RUBY) in Japan examined eating patterns and their relationship with metabolic parameters and diabetic complications. We also examined whether eating patterns affected safety and efficacy of teneligliptin. Methods: We analyzed baseline data from survey forms collected in RUBY between May 2013 and June 2017, including patient characteristics, metabolic parameters, and eating patterns (eating three meals per day or not; timing of evening meal) before teneligliptin treatment was initiated. Safety and efficacy of 12 months’ teneligliptin (20–40 mg/day) treatment was assessed. Results: Data from 10,532 patients were available for analysis. Most patients who did not eat three meals per day (n =757) or who ate their evening meal after 10 PM (n =206) were 64 years old or younger. At baseline, glycated hemoglobin (HbA1c), fasting blood glucose, triglycerides, total and low-density lipoprotein cholesterol, body mass index, alanine aminotransferase, and aspartate aminotransferase levels were higher in those patients who did not eat three meals per day (p < 0.05) or who ate their evening meal late (p < 0.05). Diabetic complications were more common in patients who did not eat three meals per day. Treatment with teneligliptin reduced HbA1c over 6 or 12 months across all eating patterns, with a low incidence of adverse drug reactions. Conclusions: Eating patterns may be associated with altered metabolic parameters and diabetic complications among Japanese patients with T2DM. Teneligliptin may be well tolerated and improve hyperglycemia in patients with T2DM irrespective of eating patterns. Funding: Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co. Ltd. Trial Registration Number: Japic CTI-153047.",
keywords = "Dipeptidyl peptidase-4 inhibitor, Eating pattern, HbA1c, Post-marketing surveillance, Teneligliptin, Type 2 diabetes",
author = "Takashi Kadowaki and Masakazu Haneda and Hiroshi Itoh and Kazuyo Sasaki and Sonoe Hiraide and Miyuki Matsukawa and Makoto Ueno",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s12325-018-0704-2",
language = "English",
volume = "35",
pages = "817--831",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "6",

}

TY - JOUR

T1 - Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment

T2 - Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients

AU - Kadowaki, Takashi

AU - Haneda, Masakazu

AU - Itoh, Hiroshi

AU - Sasaki, Kazuyo

AU - Hiraide, Sonoe

AU - Matsukawa, Miyuki

AU - Ueno, Makoto

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction: Healthy eating is a critical aspect of the prevention and management of type 2 diabetes (T2DM). Disrupted eating patterns can result in poor glucose control and increase the likelihood of diabetic complications. Teneligliptin inhibits dipeptidyl peptidase-4 activity for 24 h and suppresses postprandial hyperglycemia after all three daily meals. This interim analysis of data from the large-scale post-marketing surveillance of teneligliptin (RUBY) in Japan examined eating patterns and their relationship with metabolic parameters and diabetic complications. We also examined whether eating patterns affected safety and efficacy of teneligliptin. Methods: We analyzed baseline data from survey forms collected in RUBY between May 2013 and June 2017, including patient characteristics, metabolic parameters, and eating patterns (eating three meals per day or not; timing of evening meal) before teneligliptin treatment was initiated. Safety and efficacy of 12 months’ teneligliptin (20–40 mg/day) treatment was assessed. Results: Data from 10,532 patients were available for analysis. Most patients who did not eat three meals per day (n =757) or who ate their evening meal after 10 PM (n =206) were 64 years old or younger. At baseline, glycated hemoglobin (HbA1c), fasting blood glucose, triglycerides, total and low-density lipoprotein cholesterol, body mass index, alanine aminotransferase, and aspartate aminotransferase levels were higher in those patients who did not eat three meals per day (p < 0.05) or who ate their evening meal late (p < 0.05). Diabetic complications were more common in patients who did not eat three meals per day. Treatment with teneligliptin reduced HbA1c over 6 or 12 months across all eating patterns, with a low incidence of adverse drug reactions. Conclusions: Eating patterns may be associated with altered metabolic parameters and diabetic complications among Japanese patients with T2DM. Teneligliptin may be well tolerated and improve hyperglycemia in patients with T2DM irrespective of eating patterns. Funding: Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co. Ltd. Trial Registration Number: Japic CTI-153047.

AB - Introduction: Healthy eating is a critical aspect of the prevention and management of type 2 diabetes (T2DM). Disrupted eating patterns can result in poor glucose control and increase the likelihood of diabetic complications. Teneligliptin inhibits dipeptidyl peptidase-4 activity for 24 h and suppresses postprandial hyperglycemia after all three daily meals. This interim analysis of data from the large-scale post-marketing surveillance of teneligliptin (RUBY) in Japan examined eating patterns and their relationship with metabolic parameters and diabetic complications. We also examined whether eating patterns affected safety and efficacy of teneligliptin. Methods: We analyzed baseline data from survey forms collected in RUBY between May 2013 and June 2017, including patient characteristics, metabolic parameters, and eating patterns (eating three meals per day or not; timing of evening meal) before teneligliptin treatment was initiated. Safety and efficacy of 12 months’ teneligliptin (20–40 mg/day) treatment was assessed. Results: Data from 10,532 patients were available for analysis. Most patients who did not eat three meals per day (n =757) or who ate their evening meal after 10 PM (n =206) were 64 years old or younger. At baseline, glycated hemoglobin (HbA1c), fasting blood glucose, triglycerides, total and low-density lipoprotein cholesterol, body mass index, alanine aminotransferase, and aspartate aminotransferase levels were higher in those patients who did not eat three meals per day (p < 0.05) or who ate their evening meal late (p < 0.05). Diabetic complications were more common in patients who did not eat three meals per day. Treatment with teneligliptin reduced HbA1c over 6 or 12 months across all eating patterns, with a low incidence of adverse drug reactions. Conclusions: Eating patterns may be associated with altered metabolic parameters and diabetic complications among Japanese patients with T2DM. Teneligliptin may be well tolerated and improve hyperglycemia in patients with T2DM irrespective of eating patterns. Funding: Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co. Ltd. Trial Registration Number: Japic CTI-153047.

KW - Dipeptidyl peptidase-4 inhibitor

KW - Eating pattern

KW - HbA1c

KW - Post-marketing surveillance

KW - Teneligliptin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85047161492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047161492&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0704-2

DO - 10.1007/s12325-018-0704-2

M3 - Article

C2 - 29777520

AN - SCOPUS:85047161492

VL - 35

SP - 817

EP - 831

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 6

ER -